Piramal Enterprises Ltd
Piramal Enterprises Limited (PEL) is one of India’s leading diversified non-banking financial companies (NBFC) with assets worth ~$10 billion, with a network of over 400 branches across 26 states/Union Territories, offering a wide range of financial products and solutions across retail and wholesale lending, fund-based platforms and investments.[1]
- Market Cap ₹ 28,527 Cr.
- Current Price ₹ 1,260
- High / Low ₹ 1,275 / 737
- Stock P/E
- Book Value ₹ 1,194
- Dividend Yield 0.79 %
- ROCE 3.91 %
- ROE 1.25 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 1.06 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -3.18% over past five years.
- Company has a low return on equity of 4.29% over last 3 years.
- Dividend payout has been low at 11.7% of profits over last 3 years
- Working capital days have increased from 45.4 days to 71.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Finance Industry: Finance & Investments
Part of BSE 400 MidSmallCap Index BSE Financial Services BSE 250 SmallCap Index Nifty MidSmallcap 400 Nifty 500 Multicap 50:25:25
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,520 | 4,503 | 5,123 | 6,342 | 8,504 | 10,631 | 11,883 | 13,068 | 12,809 | 7,726 | 8,981 | 10,110 | 9,360 | |
3,086 | 3,855 | 4,233 | 4,751 | 4,997 | 5,471 | 5,264 | 6,801 | 5,338 | 1,984 | 7,434 | 6,351 | 5,809 | |
Operating Profit | 434 | 648 | 890 | 1,590 | 3,506 | 5,160 | 6,619 | 6,268 | 7,471 | 5,741 | 1,547 | 3,759 | 3,550 |
OPM % | 12% | 14% | 17% | 25% | 41% | 49% | 56% | 48% | 58% | 74% | 17% | 37% | 38% |
158 | 214 | 2,946 | 579 | 217 | 260 | 198 | 1,555 | 754 | 963 | 8,470 | -1,865 | -1,492 | |
Interest | 575 | 1,050 | 511 | 959 | 2,031 | 2,978 | 4,100 | 5,321 | 4,209 | 4,225 | 3,994 | 4,344 | 4,780 |
Depreciation | 210 | 247 | 290 | 255 | 382 | 477 | 401 | 520 | 561 | 74 | 123 | 829 | 860 |
Profit before tax | -193 | -435 | 3,035 | 954 | 1,310 | 1,964 | 2,316 | 1,982 | 3,456 | 2,405 | 5,900 | -3,278 | -3,581 |
Tax % | 13% | 14% | 11% | 5% | 17% | -146% | 37% | 99% | 59% | 17% | -69% | -49% | |
-222 | -501 | 2,850 | 905 | 1,252 | 5,120 | 1,464 | 21 | 1,413 | 1,999 | 9,969 | -1,684 | -1,896 | |
EPS in Rs | -11.14 | -24.58 | 139.70 | 44.35 | 61.39 | 250.81 | 70.26 | 1.07 | 59.08 | 80.57 | 417.62 | -74.94 | -84.45 |
Dividend Payout % | -133% | -181% | 12% | 33% | 29% | 9% | 35% | 1,314% | 56% | 41% | 7% | -13% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | -3% |
3 Years: | -8% |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | -27% |
3 Years: | -34% |
TTM: | -100% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | -7% |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 3% |
3 Years: | 4% |
Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 35 | 35 | 35 | 35 | 35 | 36 | 37 | 45 | 45 | 48 | 48 | 45 | 45 |
Reserves | 10,689 | 9,287 | 11,701 | 12,914 | 14,848 | 26,526 | 27,187 | 30,526 | 33,973 | 35,441 | 31,011 | 26,512 | 26,885 |
7,688 | 9,552 | 7,306 | 16,279 | 30,451 | 44,161 | 56,037 | 42,238 | 39,557 | 55,539 | 49,583 | 53,611 | 57,665 | |
1,832 | 2,622 | 1,891 | 1,722 | 2,875 | 2,048 | 2,333 | 2,091 | 3,321 | 8,652 | 3,110 | 2,437 | 2,162 | |
Total Liabilities | 20,244 | 21,495 | 20,933 | 30,949 | 48,209 | 72,771 | 85,594 | 74,900 | 76,896 | 99,681 | 83,752 | 82,605 | 86,756 |
5,709 | 6,191 | 7,065 | 7,525 | 9,973 | 10,726 | 11,197 | 6,415 | 7,860 | 9,133 | 3,263 | 3,389 | 3,348 | |
CWIP | 372 | 491 | 277 | 355 | 880 | 647 | 494 | 517 | 636 | 1,188 | 6 | 20 | 0 |
Investments | 7,877 | 9,446 | 7,768 | 16,317 | 25,181 | 28,842 | 25,747 | 19,443 | 22,029 | 24,857 | 22,332 | 12,513 | 12,985 |
6,285 | 5,367 | 5,823 | 6,752 | 12,176 | 32,556 | 48,156 | 48,525 | 46,371 | 64,503 | 58,151 | 66,683 | 70,423 | |
Total Assets | 20,244 | 21,495 | 20,933 | 30,949 | 48,209 | 72,771 | 85,594 | 74,900 | 76,896 | 99,681 | 83,752 | 82,605 | 86,756 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1,570 | -1,604 | -2,207 | -6,956 | -10,057 | -15,967 | -11,611 | 7,516 | 3,665 | 8,443 | 1,378 | 26 | |
-1,495 | 1,535 | 6,193 | -594 | -2,376 | -1,747 | -820 | 7,491 | -2,766 | -967 | -646 | -1,872 | |
3,281 | 126 | -3,865 | 7,544 | 13,570 | 18,650 | 10,752 | -13,019 | 2,072 | -6,774 | -3,287 | 1,390 | |
Net Cash Flow | 216 | 57 | 122 | -7 | 1,138 | 936 | -1,679 | 1,988 | 2,970 | 702 | -2,555 | -455 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 62 | 58 | 59 | 56 | 48 | 47 | 43 | 37 | 44 | 77 | 1 | 0 |
Inventory Days | 178 | 199 | 187 | 202 | 188 | 186 | 201 | 231 | 247 | |||
Days Payable | 177 | 148 | 142 | 196 | 199 | 210 | 232 | 215 | 224 | |||
Cash Conversion Cycle | 63 | 109 | 105 | 62 | 37 | 22 | 12 | 53 | 67 | 77 | 1 | 0 |
Working Capital Days | 79 | 61 | 78 | -3 | -117 | -100 | -203 | -204 | -19 | -23 | 87 | 72 |
ROCE % | 3% | 3% | 4% | 8% | 9% | 9% | 9% | 9% | 10% | 8% | 2% | 4% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
22h - Issuance of duplicate share certificates to shareholders.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
1d - Update on penalty appeal outcome for Paramount Pharma.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Schedule of Analyst/Institutional Investor Meetings.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
9 Dec - Intimation of duplicate share certificate issuance.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
6 Dec - Intimation of duplicate share certificate issuance.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024TranscriptNotesPPT
-
Oct 2024Transcript PPT
-
Sep 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021Transcript PPT
-
Oct 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Nov 2020TranscriptPPT
-
Sep 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Oct 2019Transcript PPT
-
Oct 2019TranscriptNotesPPT
-
Aug 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
May 2019TranscriptPPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Aug 2018TranscriptPPT
-
Jun 2018TranscriptPPT
-
Jun 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Nov 2017TranscriptPPT
-
Sep 2017Transcript PPT
-
May 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017Transcript PPT
-
Jan 2017TranscriptNotesPPT
-
Nov 2016TranscriptPPT
-
Mar 2016TranscriptNotesPPT
Promoters
Piramal Enterprise is the holding company of the Piramal Group headed by the Chairman, Ajay Piramal. The promoter group has a presence in diversified businesses like financial services through Piramal Enterprise, pharma (CDMO, Critical Care, OTC) through Piramal Pharma Ltd (PPL), and real estate development and consulting (through a separate company). [1]